When was the oral polio vaccine first used?

1. Underwood M. Debility of the lower extremities. In: Treatise on the diseases of children. London: J Mathews; 1789. pp. 53–57. [Google Scholar]

2. Badham J. Paralysis in childhood: four remarkable cases of suddenly induced paralysis in the extremities without any apparent cerebral or cerebrospinal lesion. London Med Gaz. 1835;17:215–218. [Google Scholar]

3. Heine J. Beobachtungen uber lahmungustande der untern extremitaten und deren behandlung. Stuttgart: FH Kohler; 1840. [Google Scholar]

4. Charcot JM, Joffroy A. Une observation de paralysie infantile s’accompagnant d’une alteration des cornes anterieures de la substance grise de la moelle. CR Soc Biol (Paris) 1870;1:312–315. [Google Scholar]

5. Putnam JJ, Taylor EW. Is acute poliomyelitis unusually prevalent this season. Boston Med Surg J. 1893;129:509–510. [Google Scholar]

6. Caverly CS. Preliminary Report of an Epidemic of Paralytic Disease Occurring in Vermont, in the Summer of 1894. Yale Med J. 1894;1:1–5. [Google Scholar]

7. Flexner S, Lewis PA. Experimental poliomyelitis in monkeys: active immunization and passive serum protection. JAMA. 1910;54:1780–1782. [Google Scholar]

8. Melnick JL. Current status of poliovirus infections. Clin Microbiol Rev. 1996;9:293–300. [PMC free article] [PubMed] [Google Scholar]

9. Paul JR. A history of poliomyelitis. New Haven, CT: Yale University Press; 1971. [Google Scholar]

10. Melnick JL. Poliomyelitis virus in urban sewage in epidemic and in nonepidemic times. Am J Hyg. 1947;45:240–253. [PubMed] [Google Scholar]

11. Melnick JL. My role in the discovery and classification of the enteroviruses. Annu Rev Microbiol. 1996;50:1–24. [PubMed] [Google Scholar]

12. Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand. 1973;1:115–118. [Google Scholar]

13. Monto AS. Francis field trial of inactivated poliomyelitis vaccine: background and lessons for today. Epidemiol Rev. 1999;21:7–23. [PubMed] [Google Scholar]

14. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992;14:568–579. [PubMed] [Google Scholar]

15. van Wezel AL, van Steenis G, van der Marel P, Osterhaus AD. Inactivated poliovirus vaccine: current production methods and new developments. Rev Infect Dis. 1984;6 Suppl 2:S335–S340. [PubMed] [Google Scholar]

16. Montagnon BJ, Fanget B, Vincent-Falquet JC. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Infect Dis. 1984;6 Suppl 2:S341–S344. [PubMed] [Google Scholar]

17. Bernier RH. Improved inactivated poliovirus vaccine: an update. Pediatr Infect Dis. 1986;5:289–292. [PubMed] [Google Scholar]

18. von Magnus H, Petersen I. Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis. 1984;6 Suppl 2:S471–S474. [PubMed] [Google Scholar]

19. Centers for Disease Control and Prevention (CDC) Progress toward global eradication of poliomyelitis, 1988-1993. MMWR Morb Mortal Wkly Rep. 1994;43:499–503. [PubMed] [Google Scholar]

20. Cook JS, Wolsing DH, Lameh J, Olson CA, Correa PE, Sadee W, Blumenthal EM, Rosenbaum JS. Characterization of the RDC1 gene which encodes the canine homolog of a proposed human VIP receptor. Expression does not correlate with an increase in VIP binding sites. FEBS Lett. 1992;300:149–152. [PubMed] [Google Scholar]

21. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, Pelon W, Michaels RH, Spigland I, Koch MA, Barnes JM, Rhim JS. Landmark article Aug 6, 1960: Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. By Albert B. Sabin, Manuel Ramos-Alvarez, José Alvarez-Amezquita, William Pelon, Richard H. Michaels, Ilya Spigland, Meinrad A. Koch, Joan M. Barnes, and Johng S. Rhim. JAMA. 1984;251:2988–2993. [PubMed] [Google Scholar]

22. Hinman AR. Landmark perspective: Mass vaccination against polio. JAMA. 1984;251:2994–2996. [PubMed] [Google Scholar]

23. Agol VI, Drozdov SG. Russian contribution to OPV. Biologicals. 1993;21:321–325. [PubMed] [Google Scholar]

24. Patriarca PA, Laender F, Palmeira G, Oliveira MJ, Lima Filho J, Dantes MC, Cordeiro MT, Risi JB, Orenstein WA. Randomised trial of alternative formulations of oral poliovaccine in Brazil. Lancet. 1988;1:429–433. [PubMed] [Google Scholar]

25. Expanded programme on immunization. Global Advisory Group--Part II. Wkly Epidemiol Rec. 1991;66:9–12. [PubMed] [Google Scholar]

26. Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med. 1994;148:479–485. [PubMed] [Google Scholar]

27. Strebel PM, Aubert-Combiescu A, Ion-Nedelcu N, Biberi-Moroeanu S, Combiescu M, Sutter RW, Kew OM, Pallansch MA, Patriarca PA, Cochi SL. Paralytic poliomyelitis in Romania, 1984-1992. Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection. Am J Epidemiol. 1994;140:1111–1124. [PubMed] [Google Scholar]

28. Cockburn WC. The work of the WHO Consultative Group on Poliomyelitis Vaccines. Bull World Health Organ. 1988;66:143–154. [PMC free article] [PubMed] [Google Scholar]

29. Strebel PM, Ion-Nedelcu N, Baughman AL, Sutter RW, Cochi SL. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine--a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med. 1995;332:500–506. [PubMed] [Google Scholar]

30. Ion-Nedelcu N, Strebel PM, Toma F, Biberi-Moroeanu S, Combiescu M, Persu A, Aubert-Combiescu A, Plotkin SA, Sutter RW. Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994. J Infect Dis. 1997;175 Suppl 1:S241–S246. [PubMed] [Google Scholar]

31. Available from: http://www.euvac.net/graphics/euvac/vaccination/vaccination.html.

32. Băicuş A, Persu A, Combiescu M, Aubert-Combiescu A. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative. Roum Arch Microbiol Immunol. 2007;66:44–50. [PubMed] [Google Scholar]

33. Combiescu M, Guillot S, Persu A, Baicus A, Pitigoi D, Balanant J, Oprisan G, Crainic R, Delpeyroux F, Aubert-Combiescu A. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania. Arch Virol. 2007;152:727–738. [PubMed] [Google Scholar]

34. Baicus A, Persu A, Dinu S, Joffret ML, Delpeyroux F, Oprisan G. The frequency and biodiversity of poliovirus and non-polio enterovirus strains isolated from healthy children living in a limited area in Romania. Arch Virol. 2011;156:701–706. [PubMed] [Google Scholar]

35. Adu F, Iber J, Bukbuk D, Gumede N, Yang SJ, Jorba J, Campagnoli R, Sule WF, Yang CF, Burns C, et al. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Res. 2007;127:17–25. [PubMed] [Google Scholar]

36. WHO. An update of ongoing research in the Global Polio Eradication Initiative. Poliopipeline. New Haven, CT: Yale University Press; 2011. Available from: http://www.polioeradication.org/Portals/0/Document/Research/PolioPipeline/PolioPipeline_08.pdf. [Google Scholar]

37. Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM, Sutter RW, Heymann DL, Aylward RB. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet. 2007;369:1356–1362. [PubMed] [Google Scholar]

38. Centers for Disease Control and Prevention (CDC) Progress toward interruption of wild poliovirus transmission--worldwide, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:308–312. [PubMed] [Google Scholar]

39. Global Polio Eradication Initiative. Monthly Situation Report (online) Geneva: WHO; 2009. Available from: http://www.polioeradication.org. [Google Scholar]

40. World Health Organization Country Office Tajikistan; WHO Regional Office for Europe; European Centre for Disease Prevention and Control. Outbreak of poliomyelitis in Tajikistan in 2010: risk for importation and impact on polio surveillance in Europe. Euro Surveill. 2010;15:pii=19558. [PubMed] [Google Scholar]

41. Centers for Disease Control and Prevention (CDC) Update on vaccine-derived polioviruses. MMWR Morb Mortal Wkly Rep. 2006;55:1093–1097. [PubMed] [Google Scholar]

42. Mohammed AJ, AlAwaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban MM, Sharif SM, van der Avoort HG, Pallansch MA, Malankar P, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010;362:2351–2359. [PubMed] [Google Scholar]

43. Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, Sarmiento L, Alemañi N, Galindo B, Burton A, Friede M, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201:1344–1352. [PubMed] [Google Scholar]

44. Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine. 2011;29:644–649. [PubMed] [Google Scholar]

45. Kreeftenberg H, van der Velden T, Kersten G, van der Heuvel N, de Bruijn M. Technology transfer of Sabin-IPV to new developing country markets. Biologicals. 2006;34:155–158. [PubMed] [Google Scholar]

46. Simizu B, Abe S, Yamamoto H, Tano Y, Ota Y, Miyazawa M, Horie H, Satoh K, Wakabayashi K. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals. 2006;34:151–154. [PubMed] [Google Scholar]

47. Aylward B, Yamada T. The polio endgame. N Engl J Med. 2011;364:2273–2275. [PubMed] [Google Scholar]